Skip to main content
. 2023 Nov 2;8:96. Originally published 2023 Feb 22. [Version 2] doi: 10.12688/wellcomeopenres.17995.2

Figure 3. PCR positivity by variant and vaccination status for symptomatic infections (index cases recruited from Pillar 2 testing and the symptomatic household contacts they infected).

Figure 3.

Lines represent median trajectories, and the ribbon is the 95% credible interval. BNT162b2, Pfizer-BioNTech mRNA vaccine; ChAdOx1, Oxford AstraZeneca adenovirus vector vaccine.